img

Global Monoclonal antibodies (mAbs) Biosimilars Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Monoclonal antibodies (mAbs) Biosimilars Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application

A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.
Monoclonal antibodies (mAbs) Biosimilars report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Monoclonal antibodies (mAbs) Biosimilars market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Anti-Cancer and Anti-Inflammatory/Autoimmune are the major drivers for the industry.
According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Monoclonal antibodies (mAbs) Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
3SBio
Accord Healthcare
AET Biotech
Allergan
Amega Biotech
Segment by Type
Erythropoietin (EPO)
Human Growth Hormone (HGH)
Granulocyte- Colony Stimulating Factor (G-CSF)
Monoclonal Antibody (mAb)
Insulin
Interferon (IFN)
Others

Segment by Application


Anti-Cancer
Anti-Inflammatory/Autoimmune
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Monoclonal antibodies (mAbs) Biosimilars market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Monoclonal antibodies (mAbs) Biosimilars introduction, etc. Monoclonal antibodies (mAbs) Biosimilars Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Monoclonal antibodies (mAbs) Biosimilars market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Market Overview of Monoclonal antibodies (mAbs) Biosimilars
1.1 Monoclonal antibodies (mAbs) Biosimilars Market Overview
1.1.1 Monoclonal antibodies (mAbs) Biosimilars Product Scope
1.1.2 Monoclonal antibodies (mAbs) Biosimilars Market Status and Outlook
1.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Overview by Region 2024 VS 2022 VS 2034
1.3 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2024-2034)
1.4 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Region (2024-2024)
1.5 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Forecast by Region (2024-2034)
1.6 Key Regions, Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034)
1.6.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034)
1.6.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034)
1.6.3 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034)
1.6.4 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034)
1.6.5 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034)
2 Monoclonal antibodies (mAbs) Biosimilars Market by Type
2.1 Introduction
2.1.1 Erythropoietin (EPO)
2.1.2 Human Growth Hormone (HGH)
2.1.3 Granulocyte- Colony Stimulating Factor (G-CSF)
2.1.4 Monoclonal Antibody (mAb)
2.1.5 Insulin
2.1.6 Interferon (IFN)
2.1.7 Others
2.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type: 2024 VS 2022 VS 2034
2.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Type (2024-2024)
2.2.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2024-2034)
2.3 Key Regions Market Size by Type
2.3.1 North America Monoclonal antibodies (mAbs) Biosimilars Revenue Breakdown by Type (2024-2034)
2.3.2 Europe Monoclonal antibodies (mAbs) Biosimilars Revenue Breakdown by Type (2024-2034)
2.3.3 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue Breakdown by Type (2024-2034)
2.3.4 Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue Breakdown by Type (2024-2034)
2.3.5 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue Breakdown by Type (2024-2034)
3 Monoclonal antibodies (mAbs) Biosimilars Market Overview by Application
3.1 Introduction
3.1.1 Anti-Cancer
3.1.2 Anti-Inflammatory/Autoimmune
3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application: 2024 VS 2022 VS 2034
3.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Application (2024-2024)
3.2.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2024-2034)
3.3 Key Regions Market Size by Application
3.3.1 North America Monoclonal antibodies (mAbs) Biosimilars Revenue Breakdown by Application (2024-2034)
3.3.2 Europe Monoclonal antibodies (mAbs) Biosimilars Revenue Breakdown by Application (2024-2034)
3.3.3 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue Breakdown by Application (2024-2034)
3.3.4 Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue Breakdown by Application (2024-2034)
3.3.5 Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue Breakdown by Application (2024-2034)
4 Monoclonal antibodies (mAbs) Biosimilars Competition Analysis by Players
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Players (2024-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2022)
4.3 Date of Key Players Enter into Monoclonal antibodies (mAbs) Biosimilars Market
4.4 Global Top Players Monoclonal antibodies (mAbs) Biosimilars Headquarters and Area Served
4.5 Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
4.6 Competitive Status
4.6.1 Monoclonal antibodies (mAbs) Biosimilars Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Biocon
5.1.1 Biocon Profile
5.1.2 Biocon Main Business
5.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
5.1.4 Biocon Monoclonal antibodies (mAbs) Biosimilars Revenue (US$ Million) & (2024-2024)
5.1.5 Biocon Recent Developments
5.2 Celltrion
5.2.1 Celltrion Profile
5.2.2 Celltrion Main Business
5.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
5.2.4 Celltrion Monoclonal antibodies (mAbs) Biosimilars Revenue (US$ Million) & (2024-2024)
5.2.5 Celltrion Recent Developments
5.3 Dr. Reddy's Laboratories
5.3.1 Dr. Reddy's Laboratories Profile
5.3.2 Dr. Reddy's Laboratories Main Business
5.3.3 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
5.3.4 Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Revenue (US$ Million) & (2024-2024)
5.3.5 Hospira Recent Developments
5.4 Hospira
5.4.1 Hospira Profile
5.4.2 Hospira Main Business
5.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
5.4.4 Hospira Monoclonal antibodies (mAbs) Biosimilars Revenue (US$ Million) & (2024-2024)
5.4.5 Hospira Recent Developments
5.5 3SBio
5.5.1 3SBio Profile
5.5.2 3SBio Main Business
5.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
5.5.4 3SBio Monoclonal antibodies (mAbs) Biosimilars Revenue (US$ Million) & (2024-2024)
5.5.5 3SBio Recent Developments
5.6 Accord Healthcare
5.6.1 Accord Healthcare Profile
5.6.2 Accord Healthcare Main Business
5.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
5.6.4 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Revenue (US$ Million) & (2024-2024)
5.6.5 Accord Healthcare Recent Developments
5.7 AET Biotech
5.7.1 AET Biotech Profile
5.7.2 AET Biotech Main Business
5.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
5.7.4 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue (US$ Million) & (2024-2024)
5.7.5 AET Biotech Recent Developments
5.8 Allergan
5.8.1 Allergan Profile
5.8.2 Allergan Main Business
5.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
5.8.4 Allergan Monoclonal antibodies (mAbs) Biosimilars Revenue (US$ Million) & (2024-2024)
5.8.5 Allergan Recent Developments
5.9 Amega Biotech
5.9.1 Amega Biotech Profile
5.9.2 Amega Biotech Main Business
5.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
5.9.4 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Revenue (US$ Million) & (2024-2024)
5.9.5 Amega Biotech Recent Developments
6 North America
6.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2024-2034)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Monoclonal antibodies (mAbs) Biosimilars Market Dynamics
11.1 Monoclonal antibodies (mAbs) Biosimilars Industry Trends
11.2 Monoclonal antibodies (mAbs) Biosimilars Market Drivers
11.3 Monoclonal antibodies (mAbs) Biosimilars Market Challenges
11.4 Monoclonal antibodies (mAbs) Biosimilars Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Monoclonal antibodies (mAbs) Biosimilars Market Size (US$ Million) Comparison by Region 2024 VS 2022 VS 2034
Table 2. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2024-2024) & (US$ Million)
Table 3. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Share by Region (2024-2024)
Table 4. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 5. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size Share by Region (2024-2034)
Table 6. Global Monoclonal antibodies (mAbs) Biosimilars Market Size (US$ Million) by Type: 2024 VS 2022 VS 2034
Table 7. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2024-2024) & (US$ Million)
Table 8. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2024-2024)
Table 9. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 10. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2024-2034)
Table 11. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2024) & (US$ Million)
Table 12. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 13. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2024) & (US$ Million)
Table 14. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 15. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2024) & (US$ Million)
Table 16. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 17. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2024) & (US$ Million)
Table 18. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 19. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2024) & (US$ Million)
Table 20. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 21. Global Monoclonal antibodies (mAbs) Biosimilars Market Size (US$ Million) by Application: 2024 VS 2022 VS 2034
Table 22. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2024-2024) & (US$ Million)
Table 23. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2024-2024)
Table 24. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2024-2034)
Table 26. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2024) & (US$ Million)
Table 27. North America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 28. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2024) & (US$ Million)
Table 29. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 30. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2024) & (US$ Million)
Table 31. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 32. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2024) & (US$ Million)
Table 33. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 34. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2024) & (US$ Million)
Table 35. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 36. Global Monoclonal antibodies (mAbs) Biosimilars Revenue (US$ Million) by Players (2024-2024)
Table 37. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Players (2024-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2022)
Table 39. Date of Key Players Enter into Monoclonal antibodies (mAbs) Biosimilars Market
Table 40. Global Monoclonal antibodies (mAbs) Biosimilars Key Players Headquarters and Area Served
Table 41. Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
Table 42. Global Monoclonal antibodies (mAbs) Biosimilars Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Biocon Basic Information List
Table 45. Biocon Description and Business Overview
Table 46. Biocon Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
Table 47. Revenue (US$ Million) in Monoclonal antibodies (mAbs) Biosimilars Business of Biocon (2024-2024)
Table 48. Biocon Recent Developments
Table 49. Celltrion Basic Information List
Table 50. Celltrion Description and Business Overview
Table 51. Celltrion Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
Table 52. Revenue (US$ Million) in Monoclonal antibodies (mAbs) Biosimilars Business of Celltrion (2024-2024)
Table 53. Celltrion Recent Developments
Table 54. Dr. Reddy's Laboratories Basic Information List
Table 55. Dr. Reddy's Laboratories Description and Business Overview
Table 56. Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
Table 57. Revenue (US$ Million) in Monoclonal antibodies (mAbs) Biosimilars Business of Dr. Reddy's Laboratories (2024-2024)
Table 58. Dr. Reddy's Laboratories Recent Developments
Table 59. Hospira Basic Information List
Table 60. Hospira Description and Business Overview
Table 61. Hospira Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
Table 62. Revenue (US$ Million) in Monoclonal antibodies (mAbs) Biosimilars Business of Hospira (2024-2024)
Table 63. Hospira Recent Developments
Table 64. 3SBio Basic Information List
Table 65. 3SBio Description and Business Overview
Table 66. 3SBio Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
Table 67. Revenue (US$ Million) in Monoclonal antibodies (mAbs) Biosimilars Business of 3SBio (2024-2024)
Table 68. 3SBio Recent Developments
Table 69. Accord Healthcare Basic Information List
Table 70. Accord Healthcare Description and Business Overview
Table 71. Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
Table 72. Revenue (US$ Million) in Monoclonal antibodies (mAbs) Biosimilars Business of Accord Healthcare (2024-2024)
Table 73. Accord Healthcare Recent Developments
Table 74. AET Biotech Basic Information List
Table 75. AET Biotech Description and Business Overview
Table 76. AET Biotech Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
Table 77. Revenue (US$ Million) in Monoclonal antibodies (mAbs) Biosimilars Business of AET Biotech (2024-2024)
Table 78. AET Biotech Recent Developments
Table 79. Allergan Basic Information List
Table 80. Allergan Description and Business Overview
Table 81. Allergan Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
Table 82. Revenue (US$ Million) in Monoclonal antibodies (mAbs) Biosimilars Business of Allergan (2024-2024)
Table 83. Allergan Recent Developments
Table 84. Amega Biotech Basic Information List
Table 85. Amega Biotech Description and Business Overview
Table 86. Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Products, Services and Solutions
Table 87. Revenue (US$ Million) in Monoclonal antibodies (mAbs) Biosimilars Business of Amega Biotech (2024-2024)
Table 88. Amega Biotech Recent Developments
Table 89. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2024) & (US$ Million)
Table 90. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034) & (US$ Million)
Table 91. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2024) & (US$ Million)
Table 92. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034) & (US$ Million)
Table 93. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 94. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2024-2024) & (US$ Million)
Table 95. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2024-2034) & (US$ Million)
Table 96. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Share by Region (2024-2024)
Table 97. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Share by Region (2024-2034)
Table 98. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 99. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2024) & (US$ Million)
Table 100. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034) & (US$ Million)
Table 101. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 102. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2024) & (US$ Million)
Table 103. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2024-2034) & (US$ Million)
Table 104. Monoclonal antibodies (mAbs) Biosimilars Market Trends
Table 105. Monoclonal antibodies (mAbs) Biosimilars Market Drivers
Table 106. Monoclonal antibodies (mAbs) Biosimilars Market Challenges
Table 107. Monoclonal antibodies (mAbs) Biosimilars Market Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Year-over-Year 2024-2034 & (US$ Million)
Figure 2. Global Monoclonal antibodies (mAbs) Biosimilars Market Size (US$ Million), 2024 VS 2022 VS 2034
Figure 3. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Regions: 2022 VS 2034
Figure 4. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size Share by Region (2024-2034)
Figure 5. North America Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 6. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 7. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 8. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 9. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 10. Product Picture of Erythropoietin (EPO)
Figure 11. Global Erythropoietin (EPO) Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 12. Product Picture of Human Growth Hormone (HGH)
Figure 13. Global Human Growth Hormone (HGH) Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 14. Product Picture of Granulocyte- Colony Stimulating Factor (G-CSF)
Figure 15. Global Granulocyte- Colony Stimulating Factor (G-CSF) Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 16. Product Picture of Monoclonal Antibody (mAb)
Figure 17. Global Monoclonal Antibody (mAb) Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 18. Product Picture of Insulin
Figure 19. Global Insulin Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 20. Product Picture of Interferon (IFN)
Figure 21. Global Interferon (IFN) Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 22. Product Picture of Others
Figure 23. Global Others Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 24. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Share by Type: 2022 & 2034
Figure 25. North America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2024-2034)
Figure 26. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2024-2034)
Figure 27. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2024-2034)
Figure 28. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2024-2034)
Figure 29. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2024-2034)
Figure 30. Anti-Cancer Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 31. Anti-Inflammatory/Autoimmune Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 32. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Share by Application: 2022 & 2034
Figure 33. North America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2024-2034)
Figure 34. Europe Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2024-2034)
Figure 35. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2024-2034)
Figure 36. Latin America Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2024-2034)
Figure 37. Middle East and Africa Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2024-2034)
Figure 38. Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 39. Global Top 5 and Top 10 Players Monoclonal antibodies (mAbs) Biosimilars Market Share in 2022
Figure 40. North America Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2024-2034)
Figure 41. U.S. Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 42. Canada Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 43. Germany Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 44. France Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 45. U.K. Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 46. Italy Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 47. Russia Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 48. Nordic Countries Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 49. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Share by Region (2024-2034)
Figure 50. China Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 51. Japan Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 52. South Korea Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 53. Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 54. India Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 55. Australia Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 56. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2024-2034)
Figure 57. Mexico Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 58. Brazil Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 59. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2024-2034)
Figure 60. Turkey Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 61. Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 62. UAE Monoclonal antibodies (mAbs) Biosimilars Market Size (2024-2034) & (US$ Million)
Figure 63. Bottom-up and Top-down Approaches for This Report